<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03348111</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/15/7854</org_study_id>
    <secondary_id>2016-A00754-47</secondary_id>
    <nct_id>NCT03348111</nct_id>
  </id_info>
  <brief_title>Establishing a New Protocol for Early Mucositis and Peri-implantitis Treatment Using an Air-polishing Device</brief_title>
  <acronym>PERIFLOW</acronym>
  <official_title>Establishing a New Protocol for Early Mucositis and Peri-implantitis Treatment Using an Air-polishing Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Considering the frequent occurence of peri-implantitis and mucositis, a multiple of treatment&#xD;
      alternatives have been proposed including non-surgical and surgical procedures. However, it&#xD;
      seems that the most effective treatment remains prevention of these diseases.&#xD;
&#xD;
      The aim of this study is to emphasize on mucositis and peri-implantitis prevention using an&#xD;
      air abrasion device the Air-Flow Master Piezon® with erythritol and chlorhexidine powder in&#xD;
      order to eliminate and / or disorganize the biofilm responsible for peri-implant mucosa&#xD;
      inflammation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peri-implant infections (mucositis and peri-implantitis) depict an increasing focus in dental&#xD;
      practice and implantology. mean prevalence of mucositis is of 43% and periimplantitis of 22%.&#xD;
      Consequences for the implant without successful treatment range from local reversible&#xD;
      inflammation (mucositis) to implant loss (periimplantitis). These lead to functional, social&#xD;
      and esthetic prejudices for patients. The main factor for establishment of peri-implant&#xD;
      infections is the formation and maturation of the bacterial biofilm. Peri-implantitis and&#xD;
      mucositis treatment require the removal of the bacterial biofilm and the disinfection of the&#xD;
      implant surface. Because of special surface conditions and structures, it is more difficult&#xD;
      to remove bacterial biofilms from implant surfaces than teeth. the key to controlling the&#xD;
      inflammation due to the bacterial biofilm is to prevent its installation and progression. The&#xD;
      procedure tested in this study is an air abrasion device, the Air-Flow Master Piezon® with&#xD;
      erythritol and chlorhexidine powders on implants presenting clinical and radiographic signs&#xD;
      of mucositis and peri-implantitis along with renewal of local oral hygiene instructions in&#xD;
      order to reduce the inflammation locally by disorganizing and eliminating the biofilm.&#xD;
      Follow-up of the patients will be held every 2 months for 6 months by scoring the bleeding on&#xD;
      probing, the plaque index and measuring clinical attachment level in order to compare it with&#xD;
      the initial measure. At 6 month an X-ray will also enable to compare bone level and&#xD;
      mineralization. This initial study will help establish a standardized protocol for&#xD;
      peri-implant infection management.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No participant enrolled&#xD;
  </why_stopped>
  <start_date type="Anticipated">June 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline peri-implant inflammation at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>bleeding on probing (binary criteria : yes/no)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline peri-implant inflammation at 4 months</measure>
    <time_frame>4 months</time_frame>
    <description>bleeding on probing (binary criteria : yes/no)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline peri-implant inflammation at 2 months</measure>
    <time_frame>2 months</time_frame>
    <description>bleeding on probing (binary criteria : yes/no)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>stability of the bone level</measure>
    <time_frame>6 months</time_frame>
    <description>bone level assessed by X-ray</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical attachment gain</measure>
    <time_frame>2 months</time_frame>
    <description>The measurement of the probing depth and of the eventual recession (compared to Baseline) allows to assess the clinical attachment gain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical attachment gain</measure>
    <time_frame>4 months</time_frame>
    <description>The measurement of the probing depth and of the eventual recession (compared to Baseline) allows to assess the clinical attachment gain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical attachment gain</measure>
    <time_frame>6 months</time_frame>
    <description>The measurement of the probing depth and of the eventual recession (compared to Baseline) allows to assess the clinical attachment gain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life with Oral Health Assessment Tool (OHAT)</measure>
    <time_frame>6 months</time_frame>
    <description>The Oral Health Assessment Tool (OHAT) was a component of the Best Practice Oral Health Model for Australian Residential Care study. The OHAT provided institutional carers with a simple, eight category screening tool to assess residents' oral health, including those with dementia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life with the Geriatric Oral Health Assessment Index (GOHAI)</measure>
    <time_frame>6 months</time_frame>
    <description>The Geriatric Oral Health Assessment Index (GOHAI) is a self-reported measure designed to assess the oral health problems of older adults</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Peri-Implantitis</condition>
  <condition>Mucositis</condition>
  <arm_group>
    <arm_group_label>Air-polishing device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Air polishing of the implant surface and/or elimination of the intrapocket biofilm using the air abrasion device Air-Flow Master Piezon®</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Air-polishing device</intervention_name>
    <description>Air abrasion using the Air-Flow Master Piezon® with erythritol and Chlorhexidine powders on implants presenting clinical and radiographic signs of mucositis and peri-implantitis along with renewal of local oral hygiene instructions in order to reduce the inflammation locally</description>
    <arm_group_label>Air-polishing device</arm_group_label>
    <other_name>Air-Flow Master Piezon®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult patients,&#xD;
&#xD;
          -  possessing one or more implants prosthetically engaged with local peri-implant mucosa&#xD;
             inflammation assessed by bleeding on probing&#xD;
&#xD;
          -  affiliated with a social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with implant mobility or implants associated with vestibular cellulitis&#xD;
&#xD;
          -  not available patients for the follow-up visits&#xD;
&#xD;
          -  patients with known allergy to erythritol and/or Chlorhexidine powder&#xD;
&#xD;
          -  patients with chronic bronchitis&#xD;
&#xD;
          -  patients with asthma&#xD;
&#xD;
          -  patients with endocarditis&#xD;
&#xD;
          -  patients with contagious disease&#xD;
&#xD;
          -  patients with immunodeficiency&#xD;
&#xD;
          -  patients under radiotherapy and/or chemotherapy and/or antibiotics&#xD;
&#xD;
          -  not mastery of plaque control on the part of the patient (after education)&#xD;
&#xD;
          -  subjects under legal protection&#xD;
&#xD;
          -  pregnant or breastfeeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara Laurencin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Toulouse (Faculty of Dental Surgery)</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>November 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mucositis</keyword>
  <keyword>Peri-Implantitis</keyword>
  <keyword>Air-Flow Master Piezon®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Peri-Implantitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

